A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases  by Fiveash, John B. et al.
Advances in Radiation Oncology (2016) 1, 83-88www.advancesradonc.orgResearch LetterA phase 2 study of radiosurgery and
temozolomide for patients with 1 to 4 brain
metastases
John B. Fiveash MD a, Waleed O. Arafat MD, PhD a,b,*,
George E. Naoum MD c, Barton L. Guthrie MD a,
Stephen M. Sawrie MD a, Sharon A. Spencer MD a,
Ruby F. Meredith MD, PhD a, James M. Markert MD, PhD a,
Robert M. Conry MD a, Burt L. Nabors MD a
a Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama
b Clinical Oncology Department, University of Alexandria, Alexandria, Egypt
c Alexandria Comprehensive Cancer Center, Alexandria, EgyptReceived 9 January 2016; received in revised form 10 March 2016; accepted 18 March 2016Abstract
Purpose: To determine if temozolomide reduces the risk of distant brain failure (DBF, meta-
chronous brain metastases) in patients with 1 to 4 brain metastases treated with radiosurgery
without whole-brain radiation therapy (WBRT).
Methods and materials: Twenty-ﬁve patients with newly diagnosed brain metastases were
enrolled in a single institution phase 2 trial of radiosurgery (15-24 Gy) and adjuvant temozolomide.
Temozolomide was continued for a total of 12 cycles unless the patient developed DBF, unac-
ceptable toxicity, or systemic progression requiring other therapy.
Results: Twenty-ﬁve patients were enrolled between 2002 and 2005; 3 were not evaluable for
determining DBF. Of the remaining 22 patients, tumor types included non-small cell lung cancer
(n Z 8), melanoma (n Z 7), and other (n Z 7). Extracranial disease was present in 10 (45%)
patients. The median number of tumors at the time of radiosurgery was 3 (range, 1-6). The median
overall survival was 31 weeks. The median radiographic follow-up for patients who did not develop
DBF was 33 weeks. Six patients developed DBF. The 1-year actuarial risk of DBF was 37%.
Conclusions: In this study, there was a relatively low risk of distant brain failure observed in the
nonmelanoma subgroup receiving temozolamide. However, patient selection factors rather than
chemotherapy treatment efﬁcacy are more likely the reason for the relatively low risk of distant
brain failure observed in this study. Future trial design should account for these risk factors.
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combinations of surgery, radiosurgery (single fraction),
and whole-brain radiation therapy (WBRT). Randomized
trials have demonstrated an improved overall survival with
the addition of either surgery or radiosurgery to WBRT for
patients with single brain metastases1,2 Although WBRT
will reduce the risk of new brain metastases in areas distant
in the brain (metachronous brain metastases) after either
surgery or radiosurgery, overall survival is not improved
with adjuvant WBRT.1,3 Although controversial, WBRT
has been implicated in neurocognitive toxicity and there
has been clinical interest in radiosurgery alone with
deferral of WBRT until progression.1,3
Temozolomide (Temodar, TMZ) is an oral imidazote-
trazine derivative and cytotoxic alkylating agent. TMZ
was developed as a potential alternative to dacarbazine in
view of its demonstrated antitumor activity and better
toxicity proﬁle in preclinical testing. The efﬁcacy of TMZ
in the treatment of newly diagnosed and relapsed primary
malignant brain tumors is now well established. Other
studies have demonstrated activity of TMZ in the treat-
ment of metastatic brain tumors. Abrey et al evaluated
response to temozolomide in 26 patients with recurrent
brain metastases. Eleven of the 26 (42%) patients had
either stable disease or partial response by magnetic
resonance imaging (MRI).4 Another phase 2 trial using
TMZ 150 mg/m2 on days 1 through 5 every 28 days found
either partial response or stable disease in 5/28 heavily
pretreated patients with brain metastases. Antonadou et al5
performed a small, randomized phase 2 study comparing
TMZ 75 mg/m2 during fractionated WBRT and then 200
mg/m2 for 5 days beginning 1 month following radiation
therapy. TMZ was continued for 6 months. Although only
28 patients were enrolled into this study, there was a sta-
tistically signiﬁcant increase in the complete response rate
with the addition of TMZ to WBRT (7/15 vs 2/13, P Z
.038). Other studies suggest that regimens containing
TMZ may decrease the incidence of new brain metastases
in patients with melanoma compared with regimens con-
taining dacarbazine. Paul et al from the United Kingdom
performed a retrospective case control study of patients
enrolled in 3 consecutive phase 2 trials evaluating various
systemic therapy regimens for stage IV melanoma that had
not metastasized to the central nervous system (CNS).
Only 2/19 patients receiving TMZ failed in the CNS
compared with 8/21 treated with regimens containing
dacarbazine. In this report, TMZ chemotherapy reduced
the incidence of CNS recurrences (P Z .0167).6 Taken
together, these early-phase studies that were done by
Mikkelsen suggest that TMZ may decrease CNS pro-
gression in patients with brain metastases.7
In this trial, we hypothesized that systemically
administered TMZ could decrease the risk of progressionof microscopic to macroscopic disease in the CNS while
radiosurgery would control the existing macroscopic
tumor. This approach might allow for the initial deferral
of WBRT in selected patients.
Because this clinical trial was designed, risk factors for
distant brain failure (DBF, metachronous brain tumors)
have been identiﬁed. A retrospective analysis of 100
patients by Sawrie et al identiﬁed number of brain
metastases (>3), melanoma histological characteristics,
and active extracranial disease as signiﬁcant independent
predictors of DBF.8 The same study stratiﬁed patients
without these risk factors into a low-risk group (with 1 year
actuarial freedom from DBF of 83%) that can beneﬁt only
from stereotactic radiosurgery alone, while making addi-
tional stereotactic radiosurgery orWBRT a salvage therapy
in case of disease progression. However, patients with the
risk factors described in this study were stratiﬁed into a
high-risk group (with a 1-year actuarial freedom from DBF
of 26%), and were better candidates for WBRT as part of
their initial treatment. Taken together, the primary endpoint
of this clinical trial is the rate of DBF (metachronous brain
tumors) to emphasize the role of our approach as an
alternative technique to WBRT in controlling DBF.
Methods and materials
After obtaining approval from the University of
Alabama at Birmingham Institutional Review Board, 25
patients with newly diagnosed brain metastases were
enrolled in a single-institution phase 2 trial of radio-
surgery (15-24 Gy) and adjuvant TMZ. Eligible patients
included those 18 years of age or older with 1 to 4 brain
metastases seen on postcontrast T1 MRI. Patients with
additional metastases seen on the day of radiosurgery
MRI scans were allowed to stay in the trial if all lesions
could be treated with radiosurgery. Eastern Cooperative
Oncology Group performance status of 0 to 1 was
required for those who had not had prior chemotherapy
and 0 to 2 for those who had received prior cytotoxic
chemotherapy. A life expectancy of at least 12 weeks was
required. Hematologic parameters included absolute
neutrophil count 1500/mm3, platelets 100,000/mm3,
hemoglobin 9 g/dL, blood urea nitrogen/creatinine
1.5X upper limit of normal (ULN), serum glutamic
pyruvic transaminase/serum glutamic oxaloacetic
transaminase/alkaline phosphatase 2x ULN if docu-
mented liver metastases, and serum glutamic pyruvic
transaminase/serum glutamic oxaloacetic transaminase/
alkaline phosphatase 5x ULN if no documented liver
metastases.
Radiosurgery was administered with either a model U
or model C Gamma Knife (Leksell). Dose prescription
was generally according to Radiation Therapy Oncology
Group 90-05 guideline9 (15-24 Gy to the 50% isodose
line), but the treating radiation oncologist was allowed to
Table 1 Patient characteristics
Patient feature No. %
Histology/tumor type
NSCLC 9 39
Melanoma 7 30
Breast 6 26
Colon 1 4
Extracranial metastases 11 48
Number of CNS metastases
at time of radiosurgery
Median 3 (range, 1-6) NA
Solitary tumor 6 26
Sex
Male 10 43
Female 13 57
Age
Mean 56 y NA
Range 23-80
RPA class
I 8 32
II 17 68
CNS, central nervous system; NA, not available; NSCLC, non-small
cell lung cancer; RPA, recursive partitioning analysis.
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apparatus was considered dose-limiting. Most patients
received TMZ with radiosurgery and were administered
150 to 200 mg/m2 by mouth each day x 5 days in 28-day
cycles. TMZ was continued for a total of 12 cycles unless
the patient developed DBF, unacceptable toxicity, or
systemic progression requiring other therapy.
Because of the heterogeneous patient population, a
matched historical control group not treated with adjuvant
temozolomide or WBRT was identiﬁed matching enrolled
patients w2:1 for number of tumors, histology (mela-
noma vs other), and presence of extracranial disease. The
risk of DBF in clinical trial patients was retrospectively
compared with the match control group.
The primary study endpoint was (metachronous brain
metastases).8,10 Secondary endpoints included toxicity,
overall survival, and quality of life as measured by
Functional Assessment of Cancer Therapy-Brain. Clin-
ical, MRI scans, and quality of life assessments were
performed after radiosurgery at 1, 3, 6, 9, 12, 15, 18, 21,
and 24 months.
For purposes of sample size calculation, the baseline
risk of DBF in patients with 1 to 4 brain metastases was
estimated to be approximately 60% at 1 year as calcu-
lated by the Kaplan-Meier method.11 Enrollment of 28
patients would have an 80% power to detect a reduction
in the 1-year risk of DBF from 60% to 30%. Because
Sawrie et al identiﬁed DBF risk factors after this trial
activation and the trial design did not include this het-
erogeneous risk of DBF, these factors have signiﬁcant
implications in the interpretation of the results of the
trial. To account for variable risk of DBF in the clinical
trial patients, a post hoc matched case control compari-
son from the University of Alabama at Birmingham
Gamma Knife database was done to account for the risk
factors that have been recently identiﬁed. Clinical trial
cases were matched to 2 controls matching the number
of tumors, histology (melanoma vs other), and presence
of extracranial metastatic tumor. The log-rank test was
used to compare the risk of DBF in the clinical trial
cohort and a match case control cohort. Independent
factors of DBF were calculation using a Cox propor-
tional hazards model.Figure 1 Number of TMZ cycles by patients.Results
Twenty-ﬁve patients were enrolled between 2002 and
2005; 3 were not evaluable for determining DBF. Patient
characteristics are shown in Table 1. Of the remaining 22
patients, tumor types included non-small cell lung cancer
(n Z 8), melanoma (n Z 7), and other (n Z 7). Extra-
cranial disease was present in 10 (45%) patients. The
median number of tumors at the time of radiosurgery was
3 (range, 1-6). The median radiographic follow-up for
patients that did not develop DBF was 33 weeks.The total number of TMZ cycles by patient is shown in
Fig 1 (mean, 3.6; range, 1-12). Most patients stopped
TMZ early because of DBF or extracranial progression
requiring other chemotherapy. One patient discontinued
TMZ because of fatigue without disease progression.
Fifteen serious adverse events occurred in the overall
group of 25 patients (Table 2). None of these was judged
to be clearly related to TMZ.
Six patients of the 22 imaging evaluable patients
developed DBF. The 1-year actuarial risk of DBF was
37% (Fig 2A). Patients with melanoma had a higher risk
of DBF than other patients (P < .001, log-rank). Only
1/15 patients without melanoma versus 5/7 patients with
melanoma developed DBF (Fig 2B). The clinical trial
group receiving adjuvant temozolomide had a trend for a
Table 2 Number of temozolomide cycles per patient
System Event Days elapsed since radiosurgery Relationship to study drug
Pulmonary Hospitalization for ruptured diverticula and
pneumonia
118 Unrelated
Death during hospitalization from
pneumonia and lung cancer
135 Unrelated
Central nervous system Hospitalization for seizures (1 day) 105 Unrelated
Hospitalization for craniotomy for
resection of necrotic tissue
146 Unrelated
Hospitalization for altered mental status 53 Unlikely
Hospitalization for dizziness 17 Unrelated
G.I.T Hospitalization for workup for new
pancreatic lesion, nausea, and vomiting
64 Unrelated
Hospitalization for heme þ stool from
colon cancer
10 Unrelated
Cardiovascular Hospitalization for DVT 18 Unrelated
Hospitalization for DVT 30 Unrelated
Hospitalization to rule out DVT 50 Unrelated
Hospitalization for chest pain and altered
mental status
164 Unlikely
Death at home of apparent heart attack (no
autopsy)
71 Unknown
Miscellaneous Hospitalization for broken hip 37 Unrelated
Hospitalization for surgery 173 Unrelated
DVT, deep vein thrombosis.
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P Z .12, log-rank test). When this relationship was
further evaluated in a Cox proportional hazards model,
the adjuvant use of temozolomide (clinical trial group)
was not an independent risk factor for DBF. The risk
stratiﬁcation scheme described by Sawrie et al8 was an
independent predictor of DBF (data not shown). In the
analysis of serial Functional Assessment of Cancer
Therapy-Brain data in the 6 patients that developed DBF,
the occurrence of DBF was not associated with a reduc-
tion in quality of life. Of these 6 patients, only 1 experi-
enced vision and speech difﬁculties as well as numbness
in the right hand and in the tongue at time of distant brain
failure and responded well to corticosteroids.Figure 2 (A) Freedom from distant brain failure. (B)As shown in Fig 3, the median overall survival was 31
weeks.Discussion
Although combinations of WBRT and radiosurgery
or surgery produce the highest rates of intracranial
tumor control over monotherapy, there remains some
controversy in how to best use WBRT in patients with
brain metastases because of the presumed risk of late
toxicity. A phase 3 randomized trial from Japan did not
ﬁnd a reduction in overall survival in patients treated with
radiosurgery alone, but the risk of tumor progression atFreedom from distant brain failure by tumor type.
Figure 3 Overall survival.
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greater in the patients who did not received WBRT. This
lower rate of CNS control was not associated with a
reduction in neurologic functional status or Mini-Mental
Status Examination scores. Despite this ﬁnding, a lower
dose of WBRT used as prophylactic cranial radiation was
associated with toxicity in patients with small cell lung
cancer. Other retrospective studies have suggested that
CNS progression after radiosurgery alone is associated
with symptoms in 71% of patients and neurologic
deﬁcits in 59%.12-14 The risk of symptoms and deﬁcits in
quality of life from the late toxicity of WBRT
versus those from brain progression has not been fully
explored in radiosurgery randomized trials that include
comprehensive neurocognitive and quality of life assess-
ments. Such studies are ongoing in the United States
(NCCTG/ACOSOG-N0574) and in Europe (European
Organization for Research and Treatment of Cancer).
However, such evidence does exist that better CNS con-
trol is associated with better survival and neurocognitive
outcomes. In a randomized trial of WBRT with or without
motexaﬁn gadolinium, tumor regression was associated
with improved survival and better ﬁne motor skills and
executive function.15-17 Because of this observation, a
strategy of treating unselected patients with radiosurgery
alone may be less desirable; thus, adding a drug to radi-
osurgery may be an attractive clinical trial strategy. In this
phase 2 clinical trial, we hypothesized that an oral
chemotherapy, TMZ, may stabilize microscopic tumor in
the brain and delay the development of new gross brain
metastases. We have provided here a proof of the prin-
ciple that WBRT can be omitted and localized radio-
surgery can be used solely with systemic available agents
that can cross the bloodebrain barrier, paving a path for
other investigator to use same principle. We aimed to
increase the number of patients but because the avail-
ability of many new drugs for melanoma and non-small
cell lung cancer we unfortunately could not recruit
more. Despite there being a small number of patients, our
results have met the aim of our approach.
This approach would potentially treat microscopic
disease present at the time of radiosurgery and preventnew cells from seeding the CNS at a later date. If suc-
cessful, it would allow for deferral of WBRT or additional
radiosurgery.
The combination of radiosurgery followed by TMZ
was well-tolerated without high grade toxicity unique to
the combination treatment. Because TMZ was dis-
continued for any systemic progression requiring other
chemotherapy, most patients received only a few cycles
of TMZ. Among the 22 patients with evaluable MRI scan
follow-up, only 6 (27% crude) patients developed DBF
with an estimated 1-year risk of 37%. Although TMZ is
often used as a frontline therapy of metastatic melanoma,
these patients had a higher risk of DBF than the non-
melanoma subgroup, as was found in a previous retro-
spective study. The melanoma patients were randomly
selected without any censoring, depending on the burden
of extracranial disease activity; therefore, additional
strategies will be needed in melanoma patients. Only 1 of
15 non-melanoma patients developed DBF, but the use of
adjuvant TMZ in this group was not an independent
predictor of DBF. However, we do not know if this
ﬁnding was attributed to TMZ effectiveness in control-
ling the disease and preventing DBF or from the non-
fulminant biological property of melanoma in these
patients.
Although combining radiosurgery with chemotherapy
is an attractive clinical trial strategy to improve CNS
control, the investigators have learned several important
factors regarding the design and logistics of this type of
study. First, new agents must be integrated into the
standard chemotherapy regimens that are used to treat
extracranial disease. In this trial, accrual was slower than
expected because many patients required chemotherapy
other than study drug TMZ. Phase 1 clinical trials of
carboplatin and paclitaxel plus TMZ have been
performed, and this might have been a better choice for
non-small cell lung cancer patients if they had active
extracranial disease.17 Similar studies have been
described for erlotinib plus TMZ (clinicaltrials.gov:
NCT00249964, NCT00268684). Second, enrichment of
the study population should be considered through
limiting enrollment to a given tumor type or through
molecular proﬁling. Finally, the risk of DBF varies
greatly by number of tumors, histology, and presence of
extracranial tumor. These factors need to be included in
the design of future studies.
In conclusion, although the use adjuvant use of TMZ
after radiosurgery was associated with a lower than ex-
pected risk of DBF, especially in non-melanoma patients.
This was likely the result of patient selection factors in
this study rather than TMZ efﬁcacy.
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